Insider Selling: FibroGen, Inc (FGEN) Director Sells $186,600.00 in Stock
FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 4,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $46.65, for a total transaction of $186,600.00. Following the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $1,399,500. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Thursday, August 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $40.74, for a total transaction of $81,480.00.
- On Monday, July 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The shares were sold at an average price of $33.45, for a total transaction of $66,900.00.
Shares of FibroGen, Inc (FGEN) opened at 51.35 on Friday. The firm’s market cap is $3.66 billion. The company’s 50-day moving average is $44.39 and its 200-day moving average is $32.56. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $53.80.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. Equities research analysts forecast that FibroGen, Inc will post ($1.80) earnings per share for the current fiscal year.
WARNING: “Insider Selling: FibroGen, Inc (FGEN) Director Sells $186,600.00 in Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/23/insider-selling-fibrogen-inc-fgen-director-sells-186600-00-in-stock.html.
Institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new stake in shares of FibroGen during the 1st quarter worth about $111,000. Quantbot Technologies LP purchased a new stake in shares of FibroGen during the 2nd quarter worth about $128,000. SG Americas Securities LLC raised its stake in shares of FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 412 shares in the last quarter. Airain ltd purchased a new stake in shares of FibroGen during the 1st quarter worth about $236,000. Finally, Amalgamated Bank purchased a new stake in shares of FibroGen during the 2nd quarter worth about $237,000. 47.49% of the stock is owned by institutional investors.
FGEN has been the subject of a number of research analyst reports. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC initiated coverage on shares of FibroGen in a research note on Monday, July 10th. They set a “buy” rating and a $50.00 price objective for the company. Citigroup Inc. reaffirmed a “buy” rating and set a $48.00 price objective on shares of FibroGen in a research note on Monday, June 26th. Finally, William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. FibroGen has a consensus rating of “Buy” and a consensus target price of $60.17.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.